Why This New Collaboration Matters For Charles River Laboratories International Stock

Charles River Laboratories International (CRL) has drawn fresh attention after announcing a collaboration with Arovella Therapeutics to provide GMP Next Generation Sequencing services for ALA-101, a CAR-iNKT cell therapy targeting certain blood cancers.

The agreement aligns with ongoing concerns about Charles River Laboratories International's core business performance, where recent summaries point to disappointing organic revenue and a projected sales decline. This makes new service partnerships an important part of the broader story.

Against this backdrop, Charles River Laboratories International's share price has moved sharply over recent months, with a 12.11% 1 month share price return and a 33.44% 3 month share price return. The 1 year total shareholder return sits at 28.06%, but the 5 year total shareholder return is down 44.32%, pointing to recent momentum after a weaker longer run.

If this kind of news driven rebound has your attention, it could be a good moment to see what else is moving in healthcare, including 39 healthcare AI stocks

The rebound in Charles River Laboratories International stock is hard to miss. However, it comes against weaker longer term returns and concerns about organic growth. Does the current price still leave enough upside to justify the risk?

Most Popular Narrative: 27.8% Undervalued

According to one of the most followed narratives on Charles River Laboratories International, the fair value of $313.61 sits well above the last close of $226.58, which frames the recent rebound in a very different light.

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry. However, the deeper implication is far more significant. The deal effectively expands and secures access to NHP supply, highlighting how critical primate availability has become in modern drug development. In other words, this acquisition reveals one of the hidden bottlenecks in the pharmaceutical research ecosystem: the supply of non-human primates.

Want to see why this narrative puts such a premium on Charles River Laboratories International? The entire valuation hangs on ambitious revenue progress, rising margins and a future earnings multiple that assumes real staying power. Curious how those ingredients combine into that $313.61 fair value and a double digit discount to the current price? The full narrative lays out each moving part in detail.

Result: Fair Value of $313.61 (UNDERVALUED)

However, this Charles River Laboratories International narrative could be challenged if organic revenue stays weak or if regulatory scrutiny around non human primate sourcing intensifies.

Another View On Charles River Laboratories International's Valuation

That 27.8% undervaluation story is not the only lens on Charles River Laboratories International. Our DCF model, which prices the stock at $121.97 based on estimated future cash flows, suggests the current $226.58 level is much higher, raising the possibility that the market is already paying up.

For investors weighing these two very different signals, the question is simple: which story feels more realistic when set against Charles River Laboratories International's current profitability and debt profile?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Charles River Laboratories International clearly split between opportunity and concern, it makes sense to move quickly and check the underlying data for yourself, weighing the 2 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond Charles River Laboratories International?

If Charles River Laboratories International has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential value opportunities early by scanning companies that look mispriced on quality and fundamentals with the 49 high quality undervalued stocks.
• Strengthen your core holdings by focusing on businesses with healthier finances using the solid balance sheet and fundamentals stocks screener (49 results).
• Uncover off the radar opportunities that still meet your quality bar through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.